https://www.selleckchem.com/products/icfsp1.html
A potentially elevated risk for pulmonary thrombosis with Janus kinase inhibitors (JAKinibs) was identified, as well as an increased risk for portal vein thrombosis, in ruxolitinib patients. Consequently, the objective of this investigation was to repeat a comprehensive analysis of the US FDA's Adverse Event Reporting System (FAERS) database to assess postmarketing reporting rates of thromboembolic events (TEs) in patients treated with JAKinibs. FAERS data (1 January 2010 to 30 September 2019) were searched for reports of all FDA-approve
Beğen
Yorum Yap
Paylaş
